Clinical Research Group Sp. z o.o.

The Warsaw site concentrates on immune‑mediated skin disorders such as Atopic Dermatitis. Research also covers Prurigo Nodularis. Studies address Hidradenitis Suppurativa.

• Upadacitinib versus dupilumab
• Long‑term safety of amlitelimab
• Eblasakimab after dupilumab failure
• Povorcitinib for Prurigo Nodularis
• Nemolizumab safety assessment

The Clinical Research Group Sp. z o.o. in Warsaw is conducting 19 studies with five investigators, all aimed at improving treatment options for immune‑related skin conditions.

Investigations target connective‑tissue diseases like Cutaneous Lupus Erythematosus. The program also includes Discoid Lupus. Another focus is Psoriasis. Additional work explores Platysma Prominence.

• Rezpegaldesleukin in moderate‑to‑severe AD
• BMS‑986165 for plaque psoriasis
• TAK‑279 oral therapy evaluation
• NT 201 for platysma prominence
• VENT‑03 in active cutaneous lupus

The Clinical Research Group Sp. z o.o. emphasizes innovative therapies to reduce skin lesions and improve quality of life for patients with lupus, psoriasis and related disorders.

Broader dermatology studies examine chronic itch conditions such as Pruritus. The research evaluates long‑term outcomes for Moderate to Severe Plaque Psoriasis.

• Dupilumab for chronic pruritus of unknown origin
• Long‑term safety of dupilumab in children
• Povorcitinib rollover (STOP‑LTR) study
• Deucravacitinib versus ustekinumab cardiovascular safety
• Extended safety of amlitelimab

At Clinical Research Group Sp. z o.o., a patient‑centered approach drives efforts to refine diagnostics and expand therapeutic choices across diverse dermatologic conditions.